MRD in CLL: some answers, many questions

被引：3
作者：
Moreno, Carol [1 ]
Mora, Alba [1 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
来源：
BLOOD | 2021年 / 138卷 / 26期
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; SURVIVAL;
D O I：
10.1182/blood.2021013435
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Wang et al compare the minimal residual disease (MRD) rate and outcome of patients with CLL treated with continuous ibrutinib plus 6 cycles of rituximab (IR) with that of those treated with FCR (fludarabine, cyclophosphamide and rituximab).(1) This study provides comparative data on the use of MRD in the management of CLL and emphasizes several pressing issues.
引用
收藏
页码：2746 / 2747
页数：2
相关论文
共 10 条
  • [1] Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
    Burger, Jan A.
    Barr, Paul M.
    Robak, Tadeusz
    Owen, Carolyn
    Ghia, Paolo
    Tedeschi, Alessandra
    Bairey, Osnat
    Hillmen, Peter
    Coutre, Steven E.
    Devereux, Stephen
    Grosicki, Sebastian
    McCarthy, Helen
    Simpson, David
    Offner, Fritz
    Moreno, Carol
    Dai, Sandra
    Lal, Indu
    Dean, James P.
    Kipps, Thomas J.
    [J]. LEUKEMIA, 2020, 34 (03) : 787 - 798
  • [2] iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
    Hallek, Michael
    Cheson, Bruce D.
    Catovsky, Daniel
    Caligaris-Cappio, Federico
    Dighiero, Guillermo
    Doehner, Hartmut
    Hillmen, Peter
    Keating, Michael
    Montserrat, Emili
    Chiorazzi, Nicholas
    Stilgenbauer, Stephan
    Rai, Kanti R.
    Byrd, John C.
    Eichhorst, Barbara
    O'Brien, Susan
    Robak, Tadeusz
    Seymour, John F.
    Kipps, Thomas J.
    [J]. BLOOD, 2018, 131 (25) : 2745 - 2760
  • [3] Ibrutinib and Venetoclax for First-Line Treatment of CLL
    Jain, Nitin
    Keating, Michael
    Thompson, Philip
    Ferrajoli, Alessandra
    Burger, Jan
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev
    Fowler, Nathan
    Kadia, Tapan
    Konopleva, Marina
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop
    Gandhi, Varsha
    Wierda, William
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22) : 2095 - 2103
  • [4] Minimal residual disease is an independent predictor for 10-year survival in CLL
    Kwok, Marwan
    Rawstron, Andy C.
    Varghese, Abraham
    Evans, Paul A. S.
    O'Connor, Sheila J. M.
    Doughty, Chi
    Newton, Darren J.
    Moreton, Paul
    Hillmen, Peter
    [J]. BLOOD, 2016, 128 (24) : 2770 - 2773
  • [5] Treatment of chronic lymphocytic leukemia: Achieving minimal residual disease-negative status as a goal
    Montserrat, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) : 2884 - 2885
  • [6] Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
    Moreno, Carol
    Greil, Richard
    Demirkan, Fatih
    Tedeschi, Alessandra
    Anz, Bertrand
    Larratt, Loree
    Simkovic, Martin
    Samoilova, Olga
    Novak, Jan
    Ben-Yehuda, Dina
    Strugov, Vladimir
    Gill, Devinder
    Gribben, John G.
    Hsu, Emily
    Lih, Chih-Jian
    Zhou, Cathy
    Clow, Fong
    James, Danelle F.
    Styles, Lori
    Flinn, Ian W.
    [J]. LANCET ONCOLOGY, 2019, 20 (01) : 43 - 56
  • [7] Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
    Roberts, Andrew W.
    Ma, Shuo
    Kipps, Thomas J.
    Coutre, Steven E.
    Davids, Matthew S.
    Eichhorst, Barbara
    Hallek, Michael
    Byrd, John C.
    Humphrey, Kathryn
    Zhou, Lang
    Chyla, Brenda
    Nielsen, Jacqueline
    Potluri, Jalaja
    Kim, Su Young
    Verdugo, Maria
    Stilgenbauer, Stephan
    Wierda, William G.
    Seymour, John F.
    [J]. BLOOD, 2019, 134 (02) : 111 - 122
  • [8] Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
    Thompson, Philip A.
    Tam, Constantine S.
    O'Brien, Susan M.
    Wierda, William G.
    Stingo, Francesco
    Plunkett, William
    Smith, Susan C.
    Kantarjian, Hagop M.
    Freireich, Emil J.
    Keating, Michael J.
    [J]. BLOOD, 2016, 127 (03) : 303 - 309
  • [9] Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
    Wang, Xin Victoria
    Hanson, Curtis A.
    Tschumper, Renee C.
    Lesnick, Connie E.
    Braggio, Esteban
    Paietta, Elisabeth M.
    O'Brien, Susan
    Barrientos, Jacqueline C.
    Leis, Jose Francisco
    Zhang, Cong Christine
    Coutre, Steven E.
    Barr, Paul M.
    Cashen, Amanda F.
    Mato, Anthony R.
    Singh, Avina K.
    Mullane, Michael P.
    Erba, Harry
    Stone, Richard
    Litzow, Mark R.
    Tallman, Martin S.
    Shanafelt, Tait D.
    Kay, Neil E.
    [J]. BLOOD, 2021, 138 (26) : 2810 - 2827
  • [10] Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
    Wierda, William G.
    Rawstron, Andrew
    Cymbalista, Florence
    Badoux, Xavier
    Rossi, Davide
    Brown, Jennifer R.
    Egle, Alexander
    Abello, Virginia
    Cervera Ceballos, Eduardo
    Herishanu, Yair
    Mulligan, Stephen P.
    Niemann, Carsten U.
    Diong, Colin P.
    Soysal, Teoman
    Suzuki, Ritsuro
    Tran, Hoa T. T.
    Wu, Shang-Ju
    Owen, Carolyn
    Stilgenbauer, Stephan
    Ghia, Paolo
    Hillmen, Peter
    [J]. LEUKEMIA, 2021, 35 (11) : 3059 - 3072
1